Arterijska hipertenzija i hronična bolesta bubrega – da li je sve pod kontrolom?

7th International Congress of Cardionephrology KARNEF (2025) [pp. 309-315]

AUTHOR(S) / AUTOR(I): Tijana Azaševac

Download Full Pdf   

DOI: 10.46793/KARNEF25.321A

ABSTRACT / SAŽETAK:

Hypertension is one of the most common diseases that affects the heart and blood vessels. The number of people suffering from chronic kidney disease is increasing, but this disease often remains unrecognized until advanced stages. Kidney diseases can be the causes of arterial hypertension, but this connection is bidirectional and hypertension often leads to the development of chronic kidney disease. Of the non-pharmacological measures, dietary Na+ restriction is particularly effective, while pharmacological treatment of arterial hypertension in these patients should be started with renin–angiotensin system blockers. Second-line therapy may include either a long-acting dihydropyridine calcium channel blocker or diuretics, while third-line therapy is a combination of all three classes of drugs.  The thiazide-like diuretic chlorthalidone is effective and can also be used in patients with advanced renal disease and uncontrolled hypertension, as well as in the treatment of resistant hypertension. Sodium-glucose cotransporter type 2 inhibitors and finerenone, although not registered as antihypertensive drugs, have this effect, and also improve renal and cardiovascular function, as well as outcomes of patients with albuminuria. Renal denervation is one of the treatment options for uncontrolled hypertension, but its effect on patients with advanced kidney disease has not yet been sufficiently studied.

 KEYWORDS / KLJUČNE REČI:

blood pressure; chronic kidney disease; hypertension; antihypertensive agents

REFERENCES / LITERATURA:

  • NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-980.
  • World Health Organization. Global report on hypertension: the race against a silent killer. Geneva, Switzerland: World Health Organization; 2023, p. 1–276.
  • Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96(5):1048-1050.
  • Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398(10302):786-802.
  • ERA Registry: ERA Registry Annual Report 2020. Amsterdam UMC, location AMC, Department of Medical Informatics, Amsterdam, the Netherlands, 2022. Available at: https://www.era-online.org/wp-content/uploads/2022/12/ERA-Registry-Annual-Report2020.pdf
  • Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314.
  • Burnier M, Damianaki A. Hypertension as Cardiovascular Risk Factor in Chronic Kidney Disease. Circ Res. 2023;132(8):1050-1063.
  • Di Lullo L, Gorini A, Russo D, Santoboni A, Ronco C; Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment. Cardiorenal Med.  2015;5(4):254–266.
  • Lv J, Ehteshami P, Sarnak MJ, Tighiouart H, Jun M, Ninomiya T et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. 2013;185(11):949-57.
  • Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials.  2011;123(24):2799-810.
  • Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV et al; SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-16.
  • Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C et al. 2017 ACC/AHA/ AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(6): 1269-1324.
  • Parati G, Stergiou GS, Bilo G, Kollias A, Pengo M, Ochoa JE et al. Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension. J Hypertens. 2021;39:1742–67.
  • Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99:S1–87.
  • Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: Core Curriculum 2019. Am J Kidney Dis. 2019;74(1):120-131.
  • Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55(13):1318–27.
  • Pugh D, Gallacher PJ, Dhaun N. Management of Hypertension in Chronic Kidney Disease. Drugs. 2019;79(4):365-379. 
  • Tanner RM, Calhoun DA, Bell EK, Bowling CB, Gutiérrez OM, Irvin MR et al. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol. 2013;8:1583–90.
  • Agarwal R, Andersen MJ. Correlates of systolic hypertension in patients with chronic kidney disease. 2005;46:514–20.
  • Agarwal R, Light RP. GFR, proteinuria and circadian blood pressure. Nephrol Dial Transplant. 2009;24:2400–6.
  • Cheigh JS, Milite C, Sullivan JF, Rubin AL, Stenzel KH. Hypertension is not adequately controlled in hemodialysis patients. Am J Kidney Dis. 1992;19(5):453-9.
  • Sarafidis PA, Persu A, Agarwal R, Burnier M, de Leeuw P, Ferro CJ et al. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). Nephrol Dial Transplant. 2017;32(4):620-640.
  • …